Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters

Deutsche medizinische Wochenschrift
J Scholze

Abstract

According to the latest health-survey data of the Robert Koch Institute, more than a fifth of all Germans are obese and about two thirds are overweight. As non-pharmacological therapies have failed to a large extent in the past, this post-marketing surveillance study was conducted to examine the feasibility, safety and efficacy of a medical weight reduction. 6360 patients with a BMI of at least 30 kg/m(2) or, in the case of further risk factors, of 27 kg/m(2) or more, were included in the trial; the inclusion criteria and exclusion criteria chosen adhered strictly to the directions of use given for sibutramine. Two thirds of the patients had concomitant diseases and/or concomitant risk factors, and 62.4 % used concomitant medications. After being informed about non-medical therapies, the patients received 10 mg sibutramine once daily. After four weeks this treatment could be continued, terminated or increased to a dosage of 15 mg sibutramine per day. The body weight was reduced from 98.4 kg to 88.4 kg within the 12 weeks of treatment, which corresponds to a mean reduction of the BMI of 3.7 kg/m (2) and which was accompanied by clinically relevant reductions of waist and hip measurements. The following metabolic parameters impro...Continue Reading

Citations

Feb 3, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J JordanA M Sharma
Feb 19, 2011·Journal of Obesity·Mariela Glandt, Itamar Raz
Jun 21, 2007·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·R Ara, A Brennan
Nov 24, 2007·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·M FlorentinM S Elisaf
Dec 7, 2006·Annals of the New York Academy of Sciences·Vojtech HainerMartin Wagenknecht
Aug 26, 2014·European Archives of Psychiatry and Clinical Neuroscience·Jochen AntelJohannes Hebebrand
Jun 28, 2007·European Heart Journal·Christian Torp-PedersenUNKNOWN SCOUT Investigators
Dec 8, 2004·International Journal of Obesity : Journal of the International Association for the Study of Obesity·V HainerM Wagenknecht
Jul 22, 2004·The Cochrane Database of Systematic Reviews·R PadwalD C W Lau
Nov 6, 2002·Circulation·Andreas L BirkenfeldJens Jordan
Oct 26, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Alan BrennanRito Bergemann
Sep 10, 2002·Current Hypertension Reports·Tobias Pischon, Arya M Sharma
Feb 25, 2009·Diabetes, Obesity & Metabolism·Souzana ChousseinStella S Daskalopoulou
May 7, 2003·Der Internist·A Wirth
Jun 28, 2005·Drugs·Lisa L Ioannides-DemosJohn J McNeil

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.